angelica
tenuissima
nakai
wide
use
commod
tradit
medicin
nevertheless
studi
conduct
antivir
immunemodulatori
properti
aqueou
extract
angelica
tenuissima
nakai
present
studi
evalu
antivir
activ
mechan
action
aqueou
extract
angelica
tenuissima
nakai
vitro
vivo
subtyp
also
found
angelica
tenuissima
nakai
induc
secret
local
iga
bronchoalveolar
lavag
fluid
balf
angelica
tenuissima
nakai
treat
mice
correl
observ
prophylact
effect
hplc
analysi
found
presenc
sever
compound
aqueou
fraction
among
evalu
antivir
properti
ferul
acid
therefor
extract
angelica
tenuissima
nakai
compon
includ
ferul
acid
play
role
immunomodul
may
potenti
candid
novel
antiviralantiinfluenza
agent
vitro
effect
dose
angelica
tenuissima
nakai
markedli
inhibit
replic
influenza
viru
vesicular
stomat
viru
vsv
herp
simplex
viru
hsv
coxsacki
viru
enteroviru
epitheli
immun
cell
inhibit
describ
induct
antivir
state
cell
antivir
ifnrel
gene
induct
secret
ifn
proinflammatori
cytokin
vivo
angelica
tenuissima
nakai
treat
balbc
mice
display
higher
surviv
lower
lung
viral
titer
challeng
lethal
dose
highli
pathogen
influenza
viral
diseas
rang
trivial
infect
plagu
alter
cours
histori
enorm
variat
virus
epidemiolog
pathogenesi
singl
magicbullet
approach
control
viru
present
set
problem
exampl
influenza
virus
highli
infecti
constitut
major
caus
agent
recurr
epidem
pandem
averag
approxim
world
popul
infect
viru
annual
result
estim
death
henc
pose
seriou
health
threat
rajasekaran
et
al
moreov
new
reemerg
infecti
viral
diseas
rise
global
health
threat
risk
spread
virus
contin
countri
even
greater
hivaid
sever
acut
respiratori
syndrom
sar
influenza
pandem
mer
epidem
mani
exampl
emerg
infecti
diseas
modern
world
moren
fauci
sever
prevent
therapeut
measur
includ
biosecur
vaccin
antivir
drug
routin
use
tri
prevent
treat
viral
diseas
vaccin
basi
prevent
mani
viral
infect
howev
consider
drawback
vaccin
requir
regular
monitor
confirm
match
vaccin
circul
viru
strain
timeconsum
gener
process
limit
avail
failur
influenza
vaccin
wide
document
elderli
populationin
mortal
occursinfluenza
vaccin
approxim
effect
reichert
et
al
eventu
pandem
infect
new
strain
antivir
drug
also
repres
first
line
defens
owe
metabol
properti
virus
difficult
control
limit
avail
associ
side
effect
rapid
develop
antivir
resist
limit
use
drug
therefor
within
evolv
environ
groundbreak
strategi
respons
requir
reduc
econom
human
health
risk
associ
viral
diseas
develop
safe
effect
inexpens
antivir
drug
among
top
global
prioriti
drug
develop
current
larg
everexpand
global
popul
base
prefer
use
natur
product
prevent
treat
medic
condit
gandhiraja
et
al
mani
pharmaceut
compani
attempt
produc
new
antimicrobi
formul
extract
plant
herb
plant
import
sourc
lead
compound
modern
drug
deriv
plant
materi
pan
et
al
viral
diseas
empir
evid
ethnomed
benefit
plant
coupl
bioassayguid
fraction
isol
potenti
identifi
novel
antivir
drug
studi
approxim
natur
orient
herbal
extract
screen
antivir
effect
extract
angelica
tenuissima
nakai
atn
show
consider
therapeut
promis
broad
spectrum
antivir
activ
immuneenhanc
properti
angelica
tenuissima
nakai
belong
famili
apiacea
grow
certain
area
china
rocki
slope
korean
peninsula
ka
et
al
wide
use
treat
headach
diarrhea
epilepsi
rheumat
arthralgia
tradit
orient
medicin
nam
et
al
howev
antivir
activ
immunemodulatori
potenti
crude
plant
extract
angelica
tenuissima
nakai
report
detail
henc
evalu
antivir
activ
total
aqueou
extract
herb
wide
array
virus
vitro
also
examin
effect
angelica
tenuissima
nakai
innat
immun
respons
addit
use
highperform
liquid
chromatographi
hplc
analysi
determin
activ
molecul
present
aqueou
fraction
commerci
dri
bark
angelica
tenuissima
nakai
obtain
verifi
professor
ki
hwan
bae
colleg
pharmaci
chungnam
nation
univers
water
extract
angelica
tenuissima
nakai
prepar
vitabio
corpor
extract
qualiti
assur
herbal
medicin
improv
research
center
korea
institut
orient
medicin
daejeon
republ
korea
hundr
gram
g
dri
bark
mix
l
distil
water
extract
heat
h
use
medic
heat
plate
gyeongseo
extractor
angelica
tenuissima
nakai
filter
use
filter
paper
millex
extract
next
centrifug
rpm
min
supernat
collect
ph
adjust
total
aqueou
extract
filter
syring
filter
lyophil
final
concentr
adjust
mgml
phosphat
buffer
salin
pb
kept
util
atcc
tm
atcc
tm
hela
atcc
tm
mdck
atcc
atcc
tm
cell
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fetal
bovin
serum
fb
gibco
antibioticantimycot
solut
gibco
humidifi
incub
co
green
fluoresc
protein
gfp
fuse
virus
vsvgfp
kindli
provid
dr
jae
u
jung
depart
molecular
microbiolog
immunolog
univers
southern
california
usa
challeng
virus
provid
dr
k
choi
chungbuk
nation
univers
cheongju
republ
korea
antivir
assay
angelica
tenuissima
nakai
pretreat
hela
cell
cell
cultur
tissu
cultur
plate
cellswel
incub
h
hela
cell
cultur
sixwel
tissu
cultur
plate
cellswel
similar
condit
antivir
assay
perform
accord
moon
et
al
modif
dmem
alon
untreat
virusonli
group
dmem
uml
recombin
mousehuman
interferon
ifn
posit
control
sigma
dmem
vv
angelica
tenuissima
nakai
incub
differ
well
hpt
hour
post
treatment
well
gentli
wash
pb
cell
infect
either
vsvgfp
moi
moi
cell
infect
vsvgfp
moi
hsvgfp
moi
hela
cell
infect
moi
moi
virus
use
dmem
contain
fb
two
hour
postinfect
hpi
cultur
medium
renew
incub
addit
h
gfp
express
observ
quantifi
glomax
multidetect
system
promega
gfp
express
viru
titrat
cell
viabil
determin
andor
hpi
vitro
proinflammatori
cytokin
induc
effect
angelica
tenuissima
nakai
test
use
commerci
elisa
kit
cell
murin
interleukin
il
measur
previous
describ
wadsworth
koop
cell
treat
recombin
murin
sigmaaldrich
vv
angelica
tenuissima
nakai
cultur
supernat
collect
hpt
clarifi
centrifug
g
min
dispens
murin
pbl
interferon
sourc
elisa
plate
murin
murin
bd
bioscienc
captur
antibodyco
elisa
plate
case
cell
recombin
human
sigmaaldrich
use
posit
control
clarifi
supernat
dispens
human
tfb
inc
human
invitrogen
elisa
plate
murin
human
human
elisa
perform
duplic
elisa
perform
triplic
interferonmedi
antivir
activ
angelica
tenuissima
nakai
determin
effect
angelica
tenuissima
nakai
type
ifnrel
protein
phosphoryl
cell
immunoblot
analysi
cell
grown
tissu
cultur
plate
incub
h
cell
treat
dmem
contain
fb
alon
neg
control
dmem
ngml
lp
posit
control
dmem
vv
angelica
tenuissima
nakai
cell
harvest
hpt
cell
pellet
lyse
lysi
buffer
immunoblot
analysi
load
sdspage
transfer
onto
polyvinyliden
difluorid
membran
biorad
h
membran
block
h
trisbuff
salin
contain
tbst
bovin
serum
albumin
incub
perform
overnight
indic
primari
antibodi
abcam
cell
signal
technolog
santa
cruz
sc
antibodi
horseradish
peroxidaseconjug
secondari
antibodi
sigma
use
visual
respect
protein
mean
enhanc
chemiluminesc
detect
system
eclg
healthcar
uk
use
mini
lumino
imag
analyz
cell
grown
tissu
cultur
plate
cellswel
incub
cell
treat
dmem
contain
fb
alon
neg
control
dmem
uml
recombin
murin
human
dmem
vv
angelica
tenuissima
nakai
cell
harvest
hpt
total
rna
cell
isol
use
rneasi
mini
kit
qiagen
cdna
synthes
use
revers
transcriptas
toyobo
differ
level
cdna
quantifi
realtim
polymeras
chain
reaction
pcr
use
quantitect
sybr
green
pcr
kit
qiagen
thermal
block
bioneer
pcr
primer
list
tabl
fifti
two
femal
fiveweekold
balbc
mice
separ
four
experiment
set
two
group
per
set
four
set
one
two
group
mice
six
lung
viru
titrat
day
postinfect
dpi
three
set
two
group
contain
mice
mice
oral
inocul
mgml
angelica
tenuissima
nakai
total
volum
day
infect
control
group
oral
inocul
pb
mice
intranas
infect
five
time
mous
lethal
dose
mice
show
bodi
weight
loss
regard
reach
experiment
end
point
human
kill
bodi
weight
surviv
record
dpi
dpi
three
mice
two
group
set
randomli
sacrif
measur
lung
viru
titer
lung
tissu
collect
euthan
mice
asept
viru
titer
measur
tissu
cultur
infecti
dose
quan
et
al
first
lung
tissu
mechan
homogen
ml
pb
solut
ad
antibioticantimycot
solut
centrifug
min
g
store
madindarbi
canin
kidney
mdck
cell
cultur
microtit
plate
infect
serial
dilut
dmem
fb
lung
homogen
quadrupl
incub
hpi
media
remov
renew
medium
contain
chloromethyl
keton
tpck
trypsin
thermo
scientif
incub
h
viral
cytopath
effect
cpe
monitor
daili
titer
determin
hemagglutin
assay
ha
viru
titer
calcul
reed
muench
method
zhao
et
al
express
tcid
lung
twenti
four
fiveweekold
balbc
mice
divid
two
group
mice
one
group
mice
oral
administ
mgml
angelica
tenuissima
nakai
total
volum
day
collect
sampl
control
group
oral
administ
pb
three
mice
group
randomli
select
hpt
angelica
tenuissimanakai
pb
bronchoalveolar
lavag
fluid
balf
smallintestin
fluid
sif
collect
describ
balf
balf
collect
previous
describ
modif
viana
et
al
briefli
lung
mice
lavag
four
time
ml
hank
balanc
salt
solut
hbss
collect
immedi
store
later
subject
elisa
murin
iga
sif
small
intestin
mice
collect
previous
describ
lyck
briefli
mice
euthan
cervic
disloc
midlin
incis
perform
retract
skin
small
intestin
cut
cm
cecum
separ
other
intestin
flush
care
hbss
sigmaaldrich
centrifug
fluid
immedi
store
sif
supernat
assay
elisa
murin
iga
reversedphas
high
perform
liquid
chromatographi
hplc
system
agil
technolog
infin
agil
technolog
co
quaternari
pump
autosampl
column
oven
multipl
wavelength
detector
pump
column
carri
zorbax
eclips
column
mm
id
um
column
oven
temperatur
kept
mobil
phase
consist
formic
acid
solvent
acetonitril
solvent
b
gradient
mode
min
b
min
b
min
b
min
b
min
b
flow
rate
mlmin
elut
monitor
nm
fraction
fr
later
identifi
confirm
ferul
acid
purifi
semi
prephplc
agil
technolog
infin
equip
fraction
collector
gilson
use
ymcpack
odsa
mm
id
nm
ymc
flow
rate
mlmin
constant
temperatur
purifi
fraction
subject
antivir
assay
cytokin
induc
abil
immun
cell
use
effect
dose
antivir
activ
cell
viru
titrat
induct
cytokin
secret
determin
accord
protocol
describ
materi
method
viral
titer
determin
standard
plaqu
assay
use
vero
cell
coil
miller
assay
viral
replic
cultur
supernat
collect
vsvgfp
infect
cell
hpi
viral
titer
determin
vero
cell
case
titrat
cell
collect
hpi
subject
five
cycl
freez
thaw
rt
titer
determin
vero
cell
viral
titer
brv
hrv
measur
median
tissu
cultur
infecti
dose
tcid
use
hela
cell
wilden
et
al
modif
briefli
supernat
collect
infect
cell
use
infect
hela
cell
cultur
microtit
plate
serial
dilut
hpi
dmem
fb
contain
tpck
trypsin
thermo
scientif
ad
infect
well
incub
addit
day
viral
cpe
observ
daili
titer
determin
hela
cell
cultur
plate
cellswel
cellswel
cellswel
respect
incub
co
atmospher
h
twofold
serial
dilut
angelica
tenuissima
nakai
ad
hpt
cell
infect
use
dmem
contain
fb
cell
infect
moi
vsvgfp
moi
cell
infect
vsvgfp
moi
hsvgfp
moi
hela
cell
infect
coxsackiegfp
moi
moi
virus
hpi
cultur
medium
renew
gfp
express
measur
hpi
glomax
multidetect
system
promega
ec
valu
calcul
angelica
tenuissima
nakai
concentr
yield
gfp
express
experi
perform
triplic
cc
assess
cell
viabil
assay
trypan
blue
exclus
strober
assay
perform
use
tissu
cultur
plate
increas
concentr
water
extract
ad
confluent
hela
cell
monolay
clarifi
cell
stain
trypan
blue
stain
invitrogen
ratio
hpt
mount
hemocytomet
get
percentag
viabl
cell
calcul
concentr
extract
result
cell
viabil
experi
perform
triplic
experi
repeat
triplic
data
assess
mean
standard
deviat
sd
statist
signific
evalu
use
student
ttest
oneway
analysi
varianc
anova
consid
signific
p
p
p
result
percent
initi
bodi
weight
also
compar
student
ttest
comparison
surviv
done
logrank
test
use
graphpad
prism
version
determin
antivir
effect
angelica
tenuissima
nakai
epitheli
cell
check
antivir
activ
hela
cell
cell
antivir
activ
determin
gfpfuse
vsv
hsv
upon
pretreat
extract
vv
upon
pretreat
fig
b
gfp
express
significantli
reduc
cell
comparison
untreat
group
show
reduc
viral
titer
nearli
vsvgfp
hsvgfp
respect
hpi
moreov
signific
reduct
cell
death
observ
angelica
tenuissima
nakai
extracttr
cell
compar
untreat
cell
also
examin
antivir
activ
angelica
tenuissima
nakai
hela
cell
gfpfuse
coxsacki
viru
pretreat
cell
angelica
tenuissima
nakai
exhibit
markedli
reduc
express
reduc
viral
titer
nearli
hpi
togeth
signific
reduct
cell
death
fig
addit
cpe
markedli
inhibit
upon
pretreat
angelica
tenuissima
nakai
fig
result
low
level
viral
replic
collect
result
indic
total
aqueou
extract
angelica
tenuissima
nakai
reduc
replic
rna
dna
virus
epitheli
cell
line
investig
antivir
effect
immun
cell
first
assess
replic
diverg
gfpexpress
virus
treat
untreat
cytotoxicfre
data
shown
angelica
tenuissima
nakai
cell
total
aqueou
extract
angelica
tenuissima
nakaitr
vv
cell
exhibit
markedli
reduc
gfp
express
howev
untreat
group
high
level
gfp
express
vsv
fig
fig
quantit
signific
reduct
gfp
express
observ
extracttr
cell
compar
untreat
group
fig
middl
panel
find
correl
observ
viral
titer
vsvgfp
infect
cell
fig
right
panel
interestingli
angelica
tenuissima
nakaitr
cell
cell
viabil
within
hpi
test
virus
compar
untreat
cell
shown
significantli
higher
cell
death
follow
viru
infect
fig
left
panel
consequ
result
also
suggest
aqueou
extract
angelica
tenuissima
nakai
could
significantli
inhibit
replic
vsv
virus
immun
cell
develop
improv
gfp
assay
determin
ec
valu
angelica
tenuissima
nakai
diverg
virus
vitro
use
cell
magadula
suleimania
lin
et
al
extract
concentr
result
reduct
viru
extract
concentr
result
cell
viabil
primarili
use
gfpfuse
virus
reduct
gfp
express
consid
equival
reduct
viru
titer
case
reduct
cpe
consid
equival
reduct
viru
titer
aqueou
extract
angelica
tenuissima
nakai
inhibit
replic
vsvgfp
hsvgfp
respect
cell
tabl
cell
vsvgfp
moi
respect
tabl
addit
observ
ec
valu
coxsackiegfp
moi
respect
hela
cell
given
effect
conveni
experi
chosen
optim
dose
angelica
tenuissima
nakai
vitro
antivir
assay
observ
ec
valu
follow
treatment
variou
concentr
cell
viabil
test
perform
assess
cytotox
angelica
tenuissima
nakai
extract
extract
hela
cell
respect
tabl
select
index
si
angelica
tenuissima
nakai
vsv
hsv
cell
respect
vsv
cell
respect
coxsacki
hela
cell
respect
notabl
si
angelica
tenuissima
nakai
sever
magnitud
higher
test
virus
respect
cell
line
clear
indic
extract
broad
prophylact
therapeut
potenti
angelica
tenuissima
nakai
possess
antivir
activ
hypothes
angelica
tenuissima
nakai
might
involv
type
ifn
signal
pathway
test
hypothesi
first
evalu
level
proinflammatori
cytokin
extracttr
cell
supernat
cell
fig
angelica
tenuissima
nakai
vv
induc
high
level
secret
cell
fig
cell
hpt
hpt
fig
importantli
secret
cytokin
amount
significantli
higher
cell
although
secret
level
high
level
observ
cell
comparison
nontreat
group
result
suggest
aqueou
extract
angelica
tenuissima
nakai
induc
secret
ifn
proinflammatori
cytokin
stimul
cellular
antivir
state
inhibit
viral
replic
check
phosphoryl
interferonrel
signal
molecul
molecul
relat
nfkb
activ
observ
correl
result
ifninduc
signal
pathway
studi
immunoblot
analys
perform
use
wholecel
lysat
angelica
tenuissima
nakaitr
vv
cell
shown
fig
found
signific
upregul
type
interferon
nfkb
relat
signal
molecul
angelica
tenuissima
nakaitr
cell
lpstreat
cell
taken
togeth
result
clearli
indic
aqueou
extract
angelica
tenuissima
nakai
induc
secret
ifn
proinflammatori
cytokin
activ
signal
molecul
type
ifn
nfkb
signal
pathway
given
angelica
tenuissima
nakai
extract
abl
secret
proinflammatori
cytokin
confirm
interact
angelica
tenuissima
nakai
transcript
level
antivir
gene
interferonstimulatori
gene
isg
vitro
confirm
realtim
pcr
assay
mrna
express
level
variou
antivir
interferon
stimulatori
gene
cell
treat
angelica
tenuissima
nakai
vv
upregul
level
similar
found
posit
control
fig
also
determin
transcript
level
variou
antivir
gene
angelica
tenuissima
nakaitr
cell
fig
realtim
pcr
assay
perform
hpt
monitor
timedepend
mrna
chang
interestingli
highest
fold
induct
cellular
transcript
level
observ
hpt
test
primer
primer
list
tabl
cell
upon
treatment
angelica
tenuissima
nakai
extract
transcript
level
upregul
respect
fig
similarli
transcript
activ
pattern
also
observ
angelica
tenuissima
nakaitr
cell
result
show
extracttr
cell
display
ninefold
increas
level
mrna
hpt
thirteenfold
induct
hpt
compar
untreat
cell
fig
henc
perform
pcr
assay
gene
interest
hpt
use
specif
primer
primer
list
tabl
cell
found
variou
antivir
gene
transcript
level
upregul
angelica
tenuissima
nakai
hpt
includ
pml
pkr
level
respect
higher
control
fig
thu
overal
result
suggest
angelica
tenuissima
nakai
extract
abl
upregul
transcript
level
isg
variou
antivir
relat
gene
cell
induc
antivir
state
studi
angelica
tenuissima
nakai
induc
prophylact
interferonmedi
antivir
activ
angelica
tenuissima
nakai
challeng
control
pb
mice
group
suffer
sever
ill
bodi
weight
loss
significantli
approxim
dpi
infect
mice
control
group
display
sever
clinic
sign
respiratori
diseas
includ
labor
respir
respiratori
distress
moreov
control
group
succumb
death
dpi
virus
test
howev
angelica
tenuissima
nakaiinocul
mice
show
bodi
weight
loss
dpi
begun
regain
dpi
return
normal
state
dpi
fig
besid
angelica
tenuissima
nakaiinocul
group
higher
surviv
rate
surviv
group
infect
fig
fig
fig
surviv
infect
fig
surviv
mice
group
show
obviou
clinic
sign
except
neglig
weight
loss
influenza
viru
transmit
primarili
aerosol
via
respiratori
system
mice
replic
induct
immun
state
angelica
tenuissima
nakai
balbc
mice
fiveweekold
femal
balbc
mice
oral
administ
mgml
angelica
tenuissima
nakai
atn
total
volum
day
collect
sampl
control
group
oral
administ
pb
three
mice
group
randomli
select
hpt
angelica
tenuissima
nakai
pb
bronchoalveolar
lavag
fluid
balf
smallintestin
fluid
sif
collect
analyz
presenc
secret
murin
b
immunoglobulin
iga
test
perform
duplic
iga
triplic
data
show
repres
mean
sd
cytokin
measur
time
p
indic
signific
differ
group
compar
student
ttest
effici
lung
bouvier
lowen
import
examin
abil
angelica
tenuissima
nakai
extract
inhibit
viral
replic
lung
evalu
abil
angelica
tenuissima
nakai
inhibit
viral
replic
infect
lung
tissu
three
mice
group
sacrif
lung
collect
day
postinfect
viral
titrat
comparison
control
group
viru
replic
effici
lung
viral
titer
log
tcid
lung
log
tcid
lung
dpi
respect
fig
compar
viral
load
angelica
tenuissima
nakaitr
group
significantli
lower
log
tcid
lung
log
dpi
dpi
respect
fig
consequ
inocul
angelica
tenuissima
nakai
extract
induc
suffici
strong
inhibit
viral
replic
endors
surviv
mice
divers
influenza
subtyp
lethal
infect
observ
immun
statu
balf
angelica
tenuissima
nakai
inocul
balbc
mice
measur
level
cytokin
iga
balf
sif
inocul
angelica
tenuissima
nakai
extract
mice
detect
signific
level
antivir
function
type
ifn
time
point
start
hpt
balf
also
detect
presenc
iga
balf
sif
test
sampl
howev
minor
level
iga
secret
detect
sampl
pbstreat
mice
fig
result
indic
oral
inocul
angelica
tenuissima
nakai
extract
stimul
mucos
immun
cell
small
intestin
ultim
induc
strong
inhibit
influenza
viru
replic
bronchoalveolar
mucos
immun
respons
system
main
compon
profil
water
extract
angelica
tenuissima
nakai
use
hplc
system
reversedphas
hplc
method
employ
mobil
phase
formic
acid
solvent
acetonitril
solvent
b
gradient
mode
follow
min
b
min
b
min
b
min
b
min
b
flow
rate
kept
constant
mlmin
total
run
time
fraction
purifi
success
evalu
antivir
effect
identifi
fraction
cell
viral
replic
monitor
respons
pretreat
variou
fraction
effect
dose
chosen
basi
preliminari
experi
efficaci
purifi
fraction
data
shown
interestingli
treatment
markedli
inhibit
viru
replic
fig
fraction
detect
wavelength
retent
time
nm
min
concentr
mgml
wv
angelica
tenuissima
nakai
extract
found
fig
b
ultim
confirm
ferul
acid
lcmass
ferul
acidtr
cell
display
reduc
gfp
express
reduc
viral
titer
compar
untreat
cell
ferul
acid
treatment
reduc
viral
titer
nearli
hpi
fig
furthermor
treatment
ferul
acid
markedli
increas
cytokin
secret
cell
fig
therefor
result
strongli
suggest
ferul
acid
major
constitu
angelica
tenuissima
nakai
might
abl
induc
antivir
state
cell
subsequ
inhibit
viru
replic
histor
natur
product
deriv
invalu
sourc
therapeut
agent
recent
technolog
advanc
coupl
unreal
expect
leadgener
strategi
led
renew
interest
natur
product
drug
discoveri
koehn
carter
plant
long
evolutionari
histori
develop
resist
virus
increasingli
drawn
attent
potenti
sourc
antivir
drug
instanc
mani
plant
extract
compound
plant
origin
shown
activ
influenza
virus
park
koehn
carter
present
plant
herb
resourc
unlimit
provid
mankind
remedi
mani
infecti
diseas
continu
play
major
role
primari
health
care
therapeut
remedi
develop
countri
evalu
antivir
activ
angelica
tenuissima
nakai
vitro
vivo
despit
known
biolog
properti
plant
studi
conduct
antivir
activ
underli
mechan
action
first
found
total
aqueou
extract
angelica
tenuissima
nakai
display
broad
spectrum
antivir
properti
vitro
herb
use
varieti
purpos
long
time
advers
effect
use
report
notabl
angelica
tenuissima
nakai
show
signific
cytotox
effect
test
cell
line
cell
cytotox
concentr
cc
sever
magnitud
higher
effect
concentr
ec
test
virus
si
herb
variou
virus
indic
higher
safeti
margin
extract
therapeut
prophylact
purpos
tabl
examin
vitro
antivir
activ
determin
angelica
tenuissima
nakai
inhibit
replic
influenza
fig
vsv
fig
hsv
fig
coxsacki
fig
fig
virus
immun
epitheli
hela
cell
upon
viral
infect
host
cell
initi
recogn
infect
quickli
evok
antivir
innat
immun
respons
includ
secret
type
ifn
proinflammatori
cytokin
takeuchi
akira
secret
ifn
cytokin
induc
antivir
state
import
protect
host
cell
invad
virus
tenoev
et
al
induct
antivir
state
earli
stage
viru
infect
critic
control
spread
pathogenesi
virus
boasso
specif
agent
could
effect
approach
limit
viral
infect
jackson
perlman
likewis
hypothes
angelica
tenuissima
nakai
induc
antivir
state
via
induct
type
interferon
proinflammatori
cytokin
determin
induct
antivir
ifnstimul
gene
fig
secret
fig
angelica
tenuissima
nakai
vitro
elucid
featur
antivir
signal
also
evalu
effect
angelica
tenuissima
nakai
phosphoryl
erk
key
signal
molecul
type
ifn
signal
pathway
upon
stimul
pattern
recognit
receptor
prr
unknown
receptor
host
cell
foreign
materi
contain
pathogen
divers
ligand
downstream
signal
transduct
activ
includ
activ
adaptor
signal
molecul
transcript
factor
initi
induct
type
ifn
proinflammatori
cytokin
upregul
antivir
statu
host
cell
mogensen
studi
found
angelica
tenuissima
nakai
extract
treatment
induc
phosphoryl
timedepend
manner
provid
evid
downstream
signal
transduct
type
ifn
signal
pathway
fig
addit
activ
lead
strong
secret
proinflammatori
cytokin
also
observ
fig
phosphoryl
could
lead
rapid
product
type
ifn
variou
inflammatori
cytokin
play
crucial
role
stimul
antivir
state
subsequ
clearanc
virus
price
et
al
oral
administr
angelica
tenuissima
nakai
extract
increas
surviv
rate
mice
subject
lethal
challeng
diverg
influenza
subtyp
includ
also
led
rapid
weight
recoveri
fig
mice
treat
abstract
initi
display
littl
weight
reduct
ultim
major
lose
bodi
weight
contrast
mice
control
group
display
weight
loss
within
dpi
human
kill
influenza
viru
caus
rapid
reduct
bodi
weight
infect
mice
henc
bodi
weight
loss
consid
human
end
point
sacrif
influenza
virusinfect
mice
addit
lung
viru
titrat
fig
correl
surviv
extracttr
mice
display
reduc
lung
viral
titer
suggest
angelica
tenuissima
nakai
suffici
potent
inhibit
viral
replic
promot
surviv
mice
lethal
infect
divers
influenza
virus
support
antivir
effect
angelica
tenuissima
nakai
vivo
observ
immun
statu
balf
angelica
tenuissima
nakai
inocul
balbc
mice
shown
fig
inocul
angelica
tenuissima
nakai
extract
mice
could
detect
signific
level
balf
previou
literatur
indic
elev
level
serum
correl
induct
antivir
state
therefor
play
import
role
inhibit
viru
replic
spellberg
edward
melchjorsen
et
al
excit
new
chapter
field
ifn
research
also
abl
activ
intracellular
signal
pathway
mani
biolog
activ
display
type
ifn
includ
antivir
activ
wide
varieti
target
cell
lazear
et
al
moreov
also
found
signific
level
secret
iga
siga
balf
sif
inocul
angelica
tenuissima
nakai
extract
secretori
iga
siga
abund
immunoglobulin
bodi
secret
includ
saliva
tear
colostrum
gastrointestin
secret
main
effector
mucos
immun
system
provid
import
first
line
defens
pathogen
invad
bodi
mucos
surfac
woof
mestecki
manti
et
al
thu
signific
level
siga
induc
balf
angelica
tenuissima
nakai
extract
mayb
correl
higher
surviv
rate
observ
balbc
mice
diverg
influenza
infect
macrophag
wide
use
drug
develop
signific
role
immun
system
especi
antivir
respons
wilden
et
al
kim
et
al
use
murin
macrophag
evalu
antivir
effect
angelica
tenuissima
nakai
vitro
addit
use
epitheli
cell
hela
suscept
viral
replic
recent
report
graham
et
al
hela
kolli
et
al
cell
fewer
prr
tolllik
receptor
tlr
find
mean
aqueou
extract
angelica
tenuissima
nakai
may
contain
activ
compon
bind
penetr
cell
membran
activ
compon
may
stimul
cell
surfac
prr
cytoplasm
prr
ultim
induc
antivir
immun
respons
immun
epitheli
cell
sure
test
angelica
tenuissima
nakai
endotoxin
contamin
use
limulu
amebocyt
lysat
lal
assay
found
contamin
endotoxin
data
shown
phytochem
report
variou
type
compound
angelica
tenuissima
nakai
includ
phthalid
coumarin
terpenoid
phenylpropanoid
islam
et
al
nam
et
al
compound
found
divers
biolog
activ
antioxid
ka
et
al
anticanc
park
et
al
angiotensin
convert
enzym
ace
inhibitori
liang
et
al
antifung
effect
confirm
report
conduct
hplc
analysi
identifi
activ
compound
present
total
aqueou
fraction
observ
major
peak
fig
fraction
success
purifi
fraction
identifi
signific
antivir
properti
like
display
angelica
tenuissima
nakai
later
confirm
ferul
acid
fig
newli
defin
antivir
effect
ferul
acid
via
type
ifn
stimul
thu
antivir
immunomodulatori
effect
aqueou
extract
angelica
tenuissima
nakai
might
due
cumul
effect
ferul
acid
includ
fraction
unknown
activ
compound
present
extract
relationship
mechan
antivir
effect
activ
compound
includ
ferul
acid
studi
interferonmedi
antivir
activ
angelica
tenuissima
nakai
summari
demonstr
aqueou
extract
angelica
tenuissima
nakai
major
altern
antivir
agent
aqueou
extract
angelica
tenuissima
nakai
inhibit
divers
viral
infect
induct
type
ifn
signal
proinflammatori
cytokin
lead
antivir
state
epitheli
immun
cell
aqueou
extract
angelica
tenuissima
nakai
reduc
influenzainduc
mortal
disrupt
viral
replic
prevent
viral
infect
creat
antivir
state
vivo
lung
given
antivir
activ
angelica
tenuissima
nakai
extract
compon
includ
ferul
acid
may
use
prevent
therapeut
agent
limit
viral
replic
caus
seriou
damag
human
livestock
furthermor
angelica
tenuissima
nakai
may
also
use
target
drug
design
prevent
viral
infect
innat
immun
respons
prasanna
weeratunga
md
bashir
uddin
design
execut
cell
biolog
experi
myunsoo
kim
byeonghoon
lee
jieun
yoon
perform
viru
infect
experi
analyz
data
jin
yeul
hongik
kim
analyz
data
jongsoo
lee
design
overal
studi
wrote
paper
anim
studi
conduct
appropri
condit
approv
institut
anim
care
use
committe
biolead
corpor
daejeon
korea
protocol
number
none
author
financi
person
relationship
peopl
organ
could
inappropri
influenc
bia
studi
